GOLDSITE SARS-COV-2&FLU A+B
4.60€
- Brand: MC EVOLUTION Srl
- Product Code: 985985124
- EAN: 6971225936211
- Availability: Out Of Stock
- Purchase 3 items for 4.51€ each
- Purchase 4 items for 4.42€ each
- Purchase 5 items for 4.32€ each
GOLDSITE
Description
This SARS-CoV-2 Influenza A/B Antigen Kit (Colloidal Gold) is a rapid lateral flow chromatographic immunoassay intended for the in vitro qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, Influenza A and Influenza B in the nose, nasopharyngeal and oropharyngeal (throat) swab specimens from individuals suspected of having a respiratory viral infection consistent with COVID-19. The results are for the identification of SARS-CoV-2, influenza A and influenza B nucleocapsid antigens, but they do not differentiate between SARS-CoV and SARS-CoV-2 viruses and are not intended to detect influenza C antigens. These Viral antigens are usually detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not exclude bacterial infection or co-infection with other viruses. The detected agent may not be the ultimate cause of the disease. Negative results should be considered presumptive, exclude neither influenza nor SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. It is recommended to confirm negative SARS-CoV-2 results with a molecular test and negative influenza A and B results with a viral culture or a molecular test as needed for patient management.
Colloidal gold-based immunochromatography is applied. The test is a combination of the SARS-CoV-2 antigen test and the influenza A/B antigen test. Briefly, SARS-CoV-2 and/or influenza A/B antigens in the sample bind to the orocolloid-labelled (detector) nucleocapsid anti-SARS-CoV-2 and/or influenza A/B antibodies on the conjugated buffer to form immune complexes. When the complexes migrate to the test line (coated with anti-SARS-CoV-2 or anti-influenza A/B nucleocapsid antibodies), the complexes containing SARS-CoV-2 and/or influenza A/antigen will be captured. b. Similarly, colloidal gold-labelled chicken IgY antibody will be captured in control lines (coated with goat chicken anti-chicken IgY). Complexes containing SARS-CoV-2 and/or influenza A/B antigen will produce a colored line in the specific region of the test line, indicating that the sample is positive for SARS-CoV-2 and/or influenza A/B antigens. Likewise, a colored line will also appear in each region of the control line indicating that the adequate volume of sample has been added and membrane wicking has occurred.
How to use
Nasal swab collection: With a gentle twist, insert the swab into one nostril. The tip of the swab should be inserted up to 2.5 cm (1 inch) from the edge of the nostril. Rotate the swab 5 times against the nasal wall. Remove and repeat the sampling process using the same swab for the other nostril.
Nasopharyngeal swab collection: Insert the swab through the nostrils perpendicular to the nose (face) until resistance is felt and fingers touch the nose. Leave the swab in place for 15-30 seconds. Rotate the swab 3 times and remove it from the nasopharynx.(c). Oropharyngeal (throat) swab: Insert the swab into the posterior pharynx and tonsillar areas. Rub the swab over both tonsillar pillars and the posterior oropharynx and avoid touching the tongue, teeth, and gums.
Samples should be tested immediately after collection. If necessary, buffer samples can be kept for
This SARS-CoV-2 Influenza A/B Antigen Kit (Colloidal Gold) is a rapid lateral flow chromatographic immunoassay intended for the in vitro qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, Influenza A and Influenza B in the nose, nasopharyngeal and oropharyngeal (throat) swab specimens from individuals suspected of having a respiratory viral infection consistent with COVID-19. The results are for the identification of SARS-CoV-2, influenza A and influenza B nucleocapsid antigens, but they do not differentiate between SARS-CoV and SARS-CoV-2 viruses and are not intended to detect influenza C antigens. These Viral antigens are usually detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not exclude bacterial infection or co-infection with other viruses. The detected agent may not be the ultimate cause of the disease. Negative results should be considered presumptive, exclude neither influenza nor SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. It is recommended to confirm negative SARS-CoV-2 results with a molecular test and negative influenza A and B results with a viral culture or a molecular test as needed for patient management.
Colloidal gold-based immunochromatography is applied. The test is a combination of the SARS-CoV-2 antigen test and the influenza A/B antigen test. Briefly, SARS-CoV-2 and/or influenza A/B antigens in the sample bind to the orocolloid-labelled (detector) nucleocapsid anti-SARS-CoV-2 and/or influenza A/B antibodies on the conjugated buffer to form immune complexes. When the complexes migrate to the test line (coated with anti-SARS-CoV-2 or anti-influenza A/B nucleocapsid antibodies), the complexes containing SARS-CoV-2 and/or influenza A/antigen will be captured. b. Similarly, colloidal gold-labelled chicken IgY antibody will be captured in control lines (coated with goat chicken anti-chicken IgY). Complexes containing SARS-CoV-2 and/or influenza A/B antigen will produce a colored line in the specific region of the test line, indicating that the sample is positive for SARS-CoV-2 and/or influenza A/B antigens. Likewise, a colored line will also appear in each region of the control line indicating that the adequate volume of sample has been added and membrane wicking has occurred.
How to use
Nasal swab collection: With a gentle twist, insert the swab into one nostril. The tip of the swab should be inserted up to 2.5 cm (1 inch) from the edge of the nostril. Rotate the swab 5 times against the nasal wall. Remove and repeat the sampling process using the same swab for the other nostril.
Nasopharyngeal swab collection: Insert the swab through the nostrils perpendicular to the nose (face) until resistance is felt and fingers touch the nose. Leave the swab in place for 15-30 seconds. Rotate the swab 3 times and remove it from the nasopharynx.(c). Oropharyngeal (throat) swab: Insert the swab into the posterior pharynx and tonsillar areas. Rub the swab over both tonsillar pillars and the posterior oropharynx and avoid touching the tongue, teeth, and gums.
Samples should be tested immediately after collection. If necessary, buffer samples can be kept for